- Home
- FDMT vs ZURA Comparison
FDMT vs ZURA Comparison
Compare FDMT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | ZURA |
|---|---|---|
| Founded | 2013 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.9M | 521.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | FDMT | ZURA |
|---|---|---|
| Price | $10.42 | $4.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $31.71 | $13.00 |
| AVG Volume (30 Days) | ★ 646.0K | 645.3K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $3.03 | $0.99 |
| 52 Week High | $12.34 | $7.25 |
Technical Indicators
Market Signals| Indicator | FDMT | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 36.70 |
| Support Level | $9.71 | $4.36 |
| Resistance Level | $10.70 | $5.82 |
| Average True Range (ATR) | 0.59 | 0.38 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 66.93 | 25.49 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.